DKSH acquires Rocephin
Antibiotic brand, pharmaceutical product · Basel, Switzerlandacquired byDKSH
DKSH acquires the rights to the antibiotic brand Rocephin from Roche in more than 80 markets. The product contains the active ingredient ceftriaxone and generated net sales of around CHF 61m in 2025.
- Buyer
- DKSH
- Target
- Rocephin, Basel
- Seller
- Roche
- Type
- Strategic
- Sector
- Healthcare & Medtech
- Country
- Switzerland
- First reported
- 28/10/2026
- Source
- cash.ch
Deal-Radar no. 44-015 · publicly reported, without guarantee · SourcingClub was not involved in this transaction. Report an error · Method
Transactions by DKSH
So far this is the only transaction by DKSH published in the Deal-Radar. New deals are added every Monday.
Strategic and succession in Week 44/2026
All deals in October 2026Every Monday, all deals of the previous week, with source.
Information from public sources, without guarantee and without claim to completeness. No investment or legal advice. Published on 30 October 2026.